Protagonist Therapeutics, Inc. (PTGX) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 4, 2021, reports the financial results for Protagonist Therapeutics, Inc. for the quarter ended June 30, 2021. The company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol PTGX.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification that the company has released its second-quarter 2021 financial results via a press release (Exhibit 99.1), which is incorporated by reference but not detailed within the body of this 8-K document.
Material Changes
No material changes or comparative financial data are disclosed in the text of this filing. The document references a press release titled "Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress" for detailed operational and financial updates.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors. It directs readers to the attached press release for information regarding recent company progress and financial condition.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q2 2021 revenue, net loss, and cash position figures.
- Verify the details of "Recent Company Progress" mentioned in the press release title, as this likely contains clinical or operational milestones.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check subsequent filings for the full financial statements referenced in this current report.